Development and testing of NK cell lines

Natural Killer Cells

Volumn , Issue , 2010, Pages 169-175

  Klingemann, Hans ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884778792     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-370454-2.00012-0     Document Type: Chapter

References (45)

1. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma - A phase I trial. Cytotherapy 2008, 10:625-632.
2. Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008, 180:6392.
3. Boissel L., Tuncer H.H., Betancur M., Wolfberg A., Klingemann H. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2007, 13:1477-1486.
4. Boissel L., Betancur M., Wels W.S., Tuncer H., Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009, 33:1255-1259.
5. Chen I.-M., Whalen M., Bankhurst A., Sever C.E., Doshi R., Hardekopf D., Montgomery K., Willman CL. A new human natural killer leukemia cell line, IMC-1. A complex chromosomal arrangement defined by spectral karyotyping: functional and cytogenetic characterization. Leuk Res 2004, 28:275-284.
6. Gong J.H., Maki G., Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1984, 8:652-658.
7. Hercend T., Reinherz E.L., Meuer S., Schlossman S.F., Ritz J. Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature 1983, 301:158.
8. Jiang W., Zhang J., Tian Z. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy 2008, 10:265-274.
9. Kagami Y., Nakamura S., Suzuki R., et al. Establishment of n IL-2 dependent cell line derived from "nasal-type" NK/T lymphoma of CD2+, sCD3-, CD3e+, CD56+ phenotype and associated with the Epstein-Barr virus. Br J Haematol 1998, 103:669-677.
10. Karre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science 1995, 267:978.
11. Klingemann H.-G., Martinson J. Ex vivo expansion of natural killer cells for clinical application. Cytotherapy 2004, 6(1):15-22.
12. Klingemann H.-G., Wong E., Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 1996, 2:68-75.
13. Konstantinidis K.V., Alici E., Aints A., Christensson B., Ljunggren H.-G., Dilber MS. Targeting IL-2 to the endoplasmatic reticulum confines autocrine growth stimulation to NK-92 cells. Exp Hematol 2005, 33:159-164.
14. Law T.M., Motzer R.J., Mazumdar M., et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995, 76:824-832.
15. Lutz C.T., Kurago ZB. Human leukocyte antigen class I expression on squamous cell carcinoma cells regulates natural killer cell activity. Cancer Res 1999, 59:5793-5799.
16. MacLeod R.A.F., Nagel F., Kaufman M., Greulich-Bode K., Drexler HG. Multicolor-FISH analysis of a natural killer cell line (NK-92). Leuk Res 2002, 26:1027-1033.
17. Maki G., Klingemann H-G., Martinson J.A., Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 2001, 10:369-383.
18. Maki G., Tam Y., Berkahn L., Klingemann H-G. Ex-vivo purging with NK-92 cells prior to autografting for chronic myelogenous leukemia. Bone Marrow Transplant 2003, 31:1119-1125.
19. Matsuo Y., Drexler H.G. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res 2003, 27:935-945.
20. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051.
21. Muller T., Uherek C., Maki G., Chow K.U., Schimpf A., Klingemann H.G., et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008, 57:411-412.
22. Nagata H., Konno A., Kimura N., et al. Characterization of novel natural killer (NK)-cell and γδ T-cell lines established from primary lesions of nasal T/NK - cell lymphomas associated with the Epstein-Barr virus. Blood 2001, 97:708-713.
23. Reid G.S., Bharya S., Klingemann H.G., Schultz KR. Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92ci cell line. Clin Exp Immunol 2002, 129:265-271.
24. Robertson M.J., Cochran K.J., Cameron C., Le J.-M., Tantravahi R., Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996, 24:406-415.
25. Rosen D.B., Cao W., Avery D.T., et al. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502.
26. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine - activated killer cells and recombinant IL-2 to patients with metastatic cancer. N Engl J Med 1985, 313:1485-1492.
27. Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J., Aebersold P., Leitman S., Linehan W.M., Seipp C.A., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993, 85(8):622-632.
28. Ruggerei L., Campanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333.
29. Sivori S., Pende D., Bottino C., Marcenaro E., Pessino A., Biassoni R., Moretta L., Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999, 29:1656.
30. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006, 16:412-418.
31. Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H-G. Characterization of genetically altered, interleukin 2 independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 1999, 10:1359-1373.
32. Tam Y.K., Miyagawa B., Ho V.C., Klingemann H-G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999, 8:281-290.
33. Tam Y., Martinson J.A., Doligosa K., Klingemann H-G. Ex vivo expansion of the highly cytotoxic human NK-92 cell line under cGMP conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003, 5:259-272.
34. Tonn T., Becker S., Esser R., Schwabe D., Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001, 10:535-544.
35. Tsuchiyama J., Yoshino T., Mori A., et al. Characterization of a novel human natural killer cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1998, 92:1374-1383.
36. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100:1265-1273.
37. Uherek C., Mueller T., Tonn T., Uherek B., Klingemann H.-G., Wels WS. Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM. Cancer Cell Int 2004, 4(Suppl. 1):S7.
38. Van de Griend R.J., van Krimpen B.A., Ronteltap C.P.M., Bolhuis R.L.H. Rapidly expanded activated human killer cell clones have strong antitumor activity and have the surface phenotype of either Tg, T-non-g, or null cells. J Immunol 1984, 132:3185.
39. Van den Broek M.F., Kagi D., Zinkernagel R.M, Hengartner H. Perforin dependence of natural killer cell mediated tumor control in vivo. Eur J Immunol 1995, 25:3514-3516.
40. Weitzman J., Betancur M., Boissel L., Rabinowitz A.P., Klein A., Klingemann H. Variable contribution of monoclonal antibodies to ADCC in CLL patients. Leuk Lymphoma 2009, 26:1-8. [Epub ahead of print].
41. Yagita M., Huang C.L., Umehara H., et al. A novel natural killer-cell line (KHYG-1) from a patient with aggressive natural killer-cell leukemia carrying a p53 point mutation. Leukemia 2000, 14:922-930.
42. Yan Y., Steinherz P., Klingemann H.-G., Denning D., Childs B.H., McGuirk J., O'Reilly RJ. Antileukemia activity of a natural killer cell line against human leukemia. Clin Cancer Res 1998, 4:2859-2868.
43. Yang S., An X., Brown R.D., Ho J., et al. Development of retargeted CD38 specific NK-92 cell line for potential anti-myeloma immunotherapy. Blood 2005, 106:5104.
44. Yengar R., Handgretinger R., Babarin-Dorner A., et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003, 5:479.
45. Yodoi J., Teshigawara K., Nikaido T., et al. TCGF (IL-2) receptor inducing factor(s). Regulation of IL-2 receptor on a natural killer-like cell line (YT cells). J Immunol 1985, 134:1623-1630.